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Abstract
Background: In tuberculosis (TB) endemic parts of the world, patients with pulmonary symptoms are managed as 
"smear-negative TB patients" if they do not improve on a two-week presumptive, broad-spectrum course of antibiotic 
treatment even if they are TB microscopy smear negative. These patients are frequently HIV positive and have a higher 
mortality than smear-positive TB patients. Lack of access to diagnose Pneumocystis jirovecii pneumonia might be a 
contributing reason. We therefore assessed the prevalence of P. jirovecii by PCR in oral wash specimens among TB 
patients and healthy individuals in an HIV- and TB-endemic area of sub-Saharan Africa.
Methods: A prospective study of 384 patients initiating treatment for sputum smear-positive and smear-negative TB 
and 100 healthy household contacts and neighbourhood controls.
DNA from oral wash specimens was examined by PCR for P. jirovecii. All patients delivered sputum for TB microscopy
and culture. Healthy contacts and community controls were clinically assessed and all study subjects were HIV tested
and had CD4 cell counts determined. Clinical status and mortality was assessed after a follow-up period of 5 months.
Results: 384 patients and 100 controls were included, 53% and 8% HIV positive respectively. A total number of 65 
patients and controls (13.6%) were at definitive risk for PCP based on CD4 counts <200 cells per mm3 and no specific 
PCP prophylaxis. Only a single patient (0.3% of the patients) was PCR positive for P. jirovecii. None of the healthy 
household contacts or neighbourhood controls had PCR-detectable P. jirovecii DNA in their oral wash specimens 
regardless of HIV-status.
Conclusions: The prevalence of P. jirovecii as detected by PCR on oral wash specimens was very low among TB patients 
with or without HIV and healthy individuals in Tanzania. Colonisation by P. jirovecii was not detected among healthy 
controls. The present findings may encourage diagnostic use of this non-invasive method.
Background
Pneumocystis jirovecii pneumonia (PCP) remains a rela-
tively common and serious opportunistic infection
among HIV infected in Western countries, even in the era
of antiretroviral therapy (ART) [1,2]. In Africa, PCP is
common and often fatal in HIV infected infants less than
1 year of age [3]. Data regarding adult patients from
Uganda [4], Malawi [5] and Ethiopia [6] have shown P.
jirovecii prevalence varying from 9% to 38% among
smear-negative, mainly HIV-positive TB patients.
The present study was inspired by results of a study
performed in Mwanza, Tanzania, in which we observed a
HIV prevalence of 63% among patients with smear-nega-
tive TB, according to WHO classification [7]. Among the
smear-positive TB patients the HIV prevalence was only
44% but the HIV-positive patients had a mortality of 23%
compared to 4% among HIV-negative patients [8]. We
considered whether undiagnosed PCP could contribute
to the excess mortality in these HIV-positive patients.
Oral wash specimens with subsequent PCR detection
of P. jirovecii DNA has been reported to be a non-invasive
and easy-to-perform procedure with a diagnostic sensi-
tivity up to 89% [9-11]. Because very little is known about
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the geographical variations in the prevalence of latent P.
jirovecii colonisation we decided to conduct a study on
the applicability of an oral wash procedure in an HIV-
and TB-endemic region of sub-Saharan Africa including
both healthy community controls, household contacts,
and clinically-ill patients suspected of pulmonary TB.
Methods
Study environment
The study was conducted in Mwanza City, North-west-
ern Tanzania from April 2007 to March 2009. The study
was a part of a TB and nutrition study (ClinicalTrials.org,
registration number NCT00311298) in which pulmonary
TB (PTB) patients were treated according to the national
guidelines for TB [12] and randomized to receive micro-
nutrients and energy-protein supplements in different
amounts.
The patients were treated according to national guide-
lines. In Tanzania, HIV testing is offered as part of the
routine medical management of TB patients [12] in line
with the UNAIDS statement 2004 [13]. The HIV preva-
lence among incident TB cases is estimated to be 47%
(year 2007) [14]. Antiretroviral treatment is available for
HIV patients and is prescribed in accordance with WHO
guidelines [15,16]. Prophylactic P. jirovecii treatment of
HIV-positive adults with co-trimoxazole is offered to
WHO stage 3 (which includes PTB) patients, to patients
with symptomatic HIV disease and to asymptomatic
HIV-positive individuals with CD4 count <200 cells per
mm3 [15].
Patient recruitment and eligibility
PTB patients diagnosed at two hospitals and two health
centres and about to start treatment under the national
TB programme were approached for participation in the
study. Exclusion criteria were: age below 15 years, preg-
nancy, terminal illness (judged unlikely to survive for 48
hours), and not staying in Mwanza for the entire 5 month
follow-up period. Patients who did not show up for 5
month follow-up and could not be traced were consid-
ered as defaulted.
One household contact and one neighbourhood con-
trol was recruited for each sputum smear-positive TB
patient. With the acceptance from the PTB patient, staff
from the study team visited the house of the PTB patient
and chose a participant by lot among the eligible house-
hold members. Lot-selected sex- and age-matched neigh-
bourhood controls were identified with the assistance of
the local ten-cell-leaders among eligible residents of the
area.
Ethical considerations
The national ethics committees in Denmark and Tanza-
nia approved the study. All participants were informed
orally in their local tongue (Kiswahili or Sukuma lan-
guage) and in writing (Kiswahili) before written consent
were obtained and they were free to withdraw from the
study at any time. Pre-HIV test counselling was provided
to the study subjects. All study subjects who were tested
for HIV received post-HIV test counselling regardless of
the result. If the HIV test was positive the subject was
referred to the local HIV programme.
TB diagnostics
All patients produced three sputum samples, of which at
least one was a morning sample, for microscopic exami-
nation after Ziehl-Neelsen staining. As part of this study,
an extra sample was obtained for control microscopy
(Auramine-O staining) and culture on Lowenstein-Jensen
solid media at the Zonal Reference Laboratory at
Bugando Medical Centre.
PTB positive patients had a positive culture and/or
microscopy positive result. PTB negative patients had a
negative culture and were found negative by microscopy
but were considered eligible for TB treatment on clinical
suspicion and chest X-ray, often after lack of improve-
ment following two weeks of presumptive broad spec-
trum antibiotic treatment. The choices of antibiotics
varied and a presumptive curative treatment was
expected to cure bacterial pneumonia.
HIV testing and CD4 counts
HIV testing was performed using Determine HIV 1/2
(Inverness Medical Innovations, Inc., Delaware, USA)
and Capillus HIV-1/HIV-2 (Trinity Biotech Plc., Wick-
low, Ireland). If discordance was found between the two
tests a confirmatory ELISA test was performed (Organon
Uniform II, Organon Teknia, NL). CD4 cell count was
determined using Partec Cyflow counter (Partec, GmbH,
Münster, FRG).
Oral wash specimens
All patients enrolled in the study had the oral wash proce-
dure performed within the first week of diagnosis and
treatment initiation of TB. The controls had the oral wash
procedure performed at the same day as all other mea-
surements were taken. The participants were fasting
since midnight and were asked to postpone brushing
their teeth until after the oral wash, which included rins-
ing/gargling the mouth with 10 ml of sterile saline for 1
min. The procedure was monitored by a staff member.
The samples were collected in sterile tubes and centri-
fuged at 3000 × g for 30 min. One ml of sediment was
stored frozen at -80°C until transfer to Denmark on dry
ice.
Detection of P. jirovecii from oral wash specimens
DNA was extracted from oral wash specimens by Chelex
extraction and 2 μl of the supernatant was used for touch-
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down-PCR detecting a fragment of the P. jirovecii mito-
chondrial large subunit rRNA gene as previously
described [10,11]. An internal process control was
included for detecting the presence of Taq DNA poly-
merase inhibitors or suboptimal reaction conditions. Pos-
itive results were confirmed by two different PCRs
amplifying mitochondrial small subunit rRNA and major
surface glycoprotein of P. jirovecii [17], respectively.
A specimen was regarded as positive for P. jirovecii
when at least two of the tests were positive. If inhibition
was observed, the test was repeated with 1 μl of the sam-
ple as template.
In order to validate the presence of human DNA in the
samples an additional PCR was performed for the detec-
tion of a 307 bp fragment of human betaglobin.
Statistical analysis
Data were collected daily onto data collection forms,
checked for accuracy and entered into EpiData version
3.1 (The EpiData Association, Odense, Denmark, 2008).
Data were exported to STATA 10.1 (StataCorp, College
Station, Texas, USA, 2009) for statistical analysis. Fishers
exact test was used to assess significant associations
among categorical variables. For numerical data Wil-
coxon-Mann-Whitney test was used.
Results
Totals of 396 PTB patients and 103 healthy controls were
enrolled. Twelve patients were excluded: One because of
lacking HIV result, 11 because of poor quality sample
material containing no detectable betaglobin DNA (7
HIV positive, 4 HIV negative). Three controls were
excluded because of poor sample material (one house-
hold contact and two neighbourhood controls) (Flow
chart depicted in Figure 1). The characteristics of the par-
ticipants are shown in Table 1. The median age was 33
years (range 15 - 89 years). The HIV-positive and HIV-
negative patients had similar median age of 34 versus 32
years (p = 0.16) and did not differ from the control group
with a median age of 32 years (p = 0.08). The gender dis-
tribution was even with 220 (45.5%) of the study subjects
being female. Mortality and loss to follow up was assessed
after five months.
HIV and PTB status
A total of 205 (53.4%) patients and 8 (8%) controls were
found to be HIV positive. 118 (57.6%) of the HIV-positive
suspected TB patients were diagnosed with smear-posi-
tive TB i.e. PTB positive. The median CD4 count for the
HIV-positive patients was 208 cells per mm3, which was
significantly lower than the median count of 387 cells per
mm3 found in the HIV-negative group (p < 0.01) and 538
cells per mm3 in the control group (p < 0.01).
CD4 count <200 cells per mm3 was noted in 112 (23%)
of all the participants, of which 94 (84%) were HIV posi-
tive. Fifteen (8%) of the HIV-negative patients and 3 (3%)
from the control group also had CD4 counts below 200
cells per mm3. The median CD4 count did not differ in
the HIV-positive, PTB negative group (219 cells per mm3)
compared to the HIV-positive, PTB positive group (203
cells per mm3) (p = 0.89).
PCP detection
Only a single patient (0.3%) tested positive with PCR for
P. jirovecii (Figure 2). This 37-year-old male patient was
HIV positive, PTB positive with CD4 count of 85 cells per
mm3. The patient was not known to be HIV positive
before study entry and had not received cotrimoxazole
treatment before study entry. The patient died about one
month after study entry at one of the hospitals where the
study took place. None of the healthy household contacts
or neighbourhood controls tested positive for P. jirovecii.
Presumptive antibiotic treatment
None of the household contacts or neighbourhood con-
trols had received antibiotics within two weeks before
enrolling the study. In contrast 175 (47%) of the TB sus-
pects had received one or more presumptive curative
courses of antibiotic treatments for two weeks before
enrolling the study. The most commonly used antibiotics
were amoxycillin, erythromycin and cotrimoxazole.
There was no difference between the pre-treatment fre-
quencies of the HIV-positive versus the HIV-negative
group (p = 0.35). 18% (35, data for 8 missing) of the HIV-
positive patients had received cotrimoxazole as opposed
to 5.9% (10, data for 10 missing) of HIV-negative patients
(p < 0.01).
Prophylactic cotrimoxazole
Prophylactic cotrimoxazole was used by 57 (58%) of the
patients, known to be HIV positive before study entry
with a median of 60 days (range 2-1095) (data missing for
12 patients). Among study subjects at risk with a CD4 cell
count <200 cells per mm3, 75 (70.1%) had not received
prophylaxis (data missing for 5 persons). Eight (53.3%) of
the HIV-positive patients, who died, knew their HIV sta-
tus at study entry. Four of them had received prophylaxis,
three of them for a median of 30 days (range 21-330)
(information on duration missing for one patient).
65 study participants (62 patients and 3 controls) had a
CD4 count <200 cells per mm3 and had neither received
prophylactic nor curative treatment with cotrimoxazole
and were therefore susceptible to P. jirovecii infection
(data missing for 5 persons).
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Dead or lost to follow up
Twenty patients (5.6%) had died at 5 months follow-up,
12 patients defaulted and 12 patients had moved away
from the region. Significantly more patients died in the
HIV-positive group, 15 (7.8%) than in the HIV-negative
group, 5 (3.0%) (p = 0.04).
No significant difference was found in the number of
patients who died between the HIV-positive, PTB nega-
tive group, 7 (8.8%) and the HIV-positive, PTB positive
group, 8 (7.1%) (p = 0.43).
Discussion
Recent studies have indicated that the incidence of symp-
tomatic PCP may have been underreported in sub-Saha-
ran Africa. P. jirovecii was diagnosed in bronchoalveolar
lavage (BAL) fluid from 9% of smear-negative, mainly
HIV-positive, TB patients in Malawi [5]. In similar stud-
ies from Ethiopia and Uganda, PCP was the definitive
diagnosis in one third of HIV-positive, PTB smear-nega-
tive patients, who underwent BAL [4,6]. In a community
based Malawian study PCP was diagnosed in only 1 per
100 person years of follow-up, but strongly correlated to
HIV status and increasing with declining CD4 count [18].
The differences in prevalence reported from different
studies may to some extent be explained by the patients
included and selection bias introduced by e.g. including
hospitalised patients versus patient referred to out
patient clinics, like in our study.
Obviously, the technical requirements and resources
needed for bronchoscopy-based procedures prevent BAL
as a routine option in low-income settings. Induced spu-
tum procedures are aerosol inducing and difficult to han-
dle safely especially when applied to patients suspected of
TB. A diagnostic method based on oral wash specimens
is a non-invasive, easily-obtained procedure but the sen-
sitive PCR entails the risk of also detecting DNA in per-
sons only colonised with P. jirovecii. Reported carrier
frequencies vary in different populations using different
PCR methods. A study from Spain found Pneumocystis
DNA in 20% of oral wash specimens from 50 healthy -
but hospital-affiliated persons [19]. A small study of 44
HIV-infected adults from the USA detected colonization
in 11.4% using a nested PCR method [20]. P. jirovecii
DNA was detected in 18% of BAL fluids from HIV-nega-
tive pulmonary patients undergoing bronchoscopy for
other reasons especially if treated with prednisolone [21].
A study of autopsy samples from American HIV patients,
who had died from other reasons than PCP had P.
Table 1: Characteristics of study subjects








Number of study subjects 484 205 179 51 49
Female (%) 220 (45.5) 99 (48.3) 64 (36.0) 33 (64.7) 24 (49.0)
Age median (range) 33 (15-89) 34 (19-70) 32 (15-89) 32 (18-86) 33 (16-55)
Males 36 (15-89) 37 (23-70) 35 (15-89) 36 (18-60) 32 (16-55)
Females 32 (16-86) 32 (19-60) 30 (18-77) 30 (18-86) 33 (16-55)
HIV positive (%) 213 (44.0) 205 (100) 0 6 (11.8) 2 (4.1)
TB positive (%) 250 (65.1) 118 (57.6) 132 (73.7) - -
CD4* median (range) 340 (21-2117) 208 (21-926) 387 (49-1609) 622 (146-1714) 465 (180-2117)
CD4* < 200 (%) 112 (23.1) 94 (45.9) 15 (8.4) 1 (2.0) 2 (4.1)
Receiving presumptive 
antibiotic treatment (%)
175 (46.5) 98 (49.0) 77 (43.8) - -
Receiving presumptive 
curative TMX**(%)
45 (12.3) 35 (17.8) 10 (5.9) - -
Receiving prophylactic 
TMX**1 (%)
57 (57.6) 57 (57.6) - - -
All: Information on sex was missing for 1 patient, age was missing for 1 patient, information on presumptive antibiotic treatment was missing 
for 8 patients, information on presumptive curative TMX missing for 10 patients.
HIV positive: information on presumptive antibiotic treatment was missing for 5 patients. Information on presumptive curative TMX was 
missing for 3 patients.
HIV negative: age missing for 1 patient, sex missing for 1 patient. Information regarding presumptive antibiotic treatment was missing for 3 
patients, information on presumptive curative TMX missing for 7 patients.
*CD4, number of CD4 cells per mm3. **TMX: cotrimoxazole
1 Number of patients receiving prophylactic TMX out of all patients known HIV positive before study entry.
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Figure 1 Study recruitment and flow chart. PTB patients: 11 were excluded because betaglobin PCR was negative (7 HIV positive, 4 HIV negative) 
and 1 because HIV status was missing. Controls: 3 were excluded because betaglobin PCR was negative (1 household contact and 2 neighbourhood 
controls).
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jirovecii DNA detectable by a sensitive, nested PCR
method in 42 of 91 subjects [22].
In this study only one of 384 patients suspected of TB
tested positive for P. jirovecii. The patient was HIV posi-
tive with a CD4 count of 83 per mm3, no prior prophylac-
tic or curative treatment attempts with cotrimoxazole,
and the clinical course resulting in death after two
months of TB treatment supports the diagnosis. The low
infection rate may be ascribed to a higher PCP prophy-
laxis coverage in this study compared to the Ethiopian,
Ugandan and Malawian studies [4-6]. In this study, 58%
of the known HIV positive patients at risk actually
received prophylaxis. However, a large group of 65
patients and controls (13.6% of the total study popula-
tion) fulfilling the criteria for prophylaxis had not
received prophylaxis or presumptive cotrimoxazole cura-
tive treatment and were therefore susceptible to P.
jirovecii infection. Recalculating the PCP prevalence for
the TB patient subgroup results in a rate of 1.6% (CI: 0-
9.8), which is overlapping the rates found in the Malawian
study by Hargreaves et al. [5]. Twenty patients died dur-
ing the five months of observation and 24 were lost to fol-
low up. The mortality was higher in the HIV-positive
than in the HIV-negative group (p = 0.04), but in this
study only part of the excess mortality could be explained
by PCP.
None of the 100 healthy household contacts and neigh-
bourhood controls tested positive for P. jirovecii. The car-
rier frequency seems to be low or at least below the
detection limit of the PCR method applied in this study.
The sensitivity of the P. jirovecii specific PCR used in this
study has in other settings been shown to detect 89% of
PCPs using Giemsa and immunofluorescence staining of
bronchoalveolar fluid as reference material [10]. It might
be possible to increase the diagnostic sensitivity by asking
the patients to cough before the oral wash to mobilise
material from lower parts of the respiratory tract. How-
ever, a PCR detecting a segment of the human betaglobin
gene was performed in order to assure the presence of
amplifiable DNA fragments and thereby assess the qual-
ity of the sample material. The length of the betaglobin
PCR product was similar to the P. jirovecii target. Only 14
participants were excluded from the study due to absence
of amplifiable DNA in the samples, suggesting that the
performance of the present study is similar to other stud-
ies in which the same PCR method was used. Colonisa-
tion may occur transiently and therefore some studies
have examined repeated samples obtained at different
time points [19]. The relatively high number of study par-
ticipants to some extent counteracts this problem.
Conclusion
This study did not support the hypothesis that coloniza-
tion with P. jirovecii is widespread, at least not in this sub-
Saharan region although larger studies would be needed
to support this. If confirmed, this may increase the appli-
cability of the very easy-to-perform oral wash procedure
as a supplement in the diagnosis of the otherwise lethal
PCP in HIV-positive patients with respiratory symptoms.
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